Fabry Disease: Preclinical Studies Demonstrate the Effectiveness of α-Galactosidase A Replacement in Enzyme-Deficient Mice

Yiannis A. Ioannou(Icahn School of Medicine at Mount Sinai), Robert J. Desnick(Icahn School of Medicine at Mount Sinai), Ken M. Zeidner(New York University), Ronald E. Gordon(New York University)
The American Journal of Human Genetics
January 1, 2001
10.1086/316953
Cited by 201

Related Papers

Niemann-Pick C1 Disease Gene: Homology to Mediators of Cholesterol Homeostasis
|Science|1997|1.5k
Agalsidase-Beta Therapy for Advanced Fabry Disease
|Annals of Internal Medicine|2007|565
Acid sphingomyelinase deficient mice: a model of types A and B Niemann–Pick disease
|Nature Genetics|1995|477
Functional variants in the <i>LRRK2</i> gene confer shared effects on risk for Crohn’s disease and Parkinson’s disease
|Science Translational Medicine|2018|410
Hepatic Niemann-Pick C1–like 1 regulates biliary cholesterol concentration and is a target of ezetimibe
|Journal of Clinical Investigation|2007|372